Aktiesnakken — Juni 2011
-
Måske derfor deres seneste vindmølle er med gear, da de ikke gider bruge penge på at udvikle direct drive..
-
Man kan læse lidt om teknologien her: http://www.amsc.com/products/applications/windEnergy/seatitan.html
-
-
haha - det gør GEN vist heller ikke
-
det må sige en del om min intelligens, at jeg stadig overraskes over, at der er fald tilbage i GEN
-
-
det tror jeg du skal - jeg kommer fint igennem.
-
den sædvanlige historie om at pharma gerne vil ind i immunterapi til cancerbehandling.
-
artiklen taler om to produkter: Dendreon Corp.s (DNDN) Provenge and Bristol-Myers
Squibb Co.s (BMY) Yervoy, so-called immunotherapies -
nævner dog ikke gen eller arzerra
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind